Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells

Sun J. Lee, Kwang Won Lee

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Advanced glycation endproducts (AGEs) are believed to be secondary factors in the selective neuronal injury associated with several neurodegenerative disorders. In this study, we investigated the protective effects of (-)-epigallocatechin gallate (EGCG), a major monomer of green tea polyphenols, against AGEs-induced damage in neuron cells. The results showed that EGCG treatment protected against glyceraldehyde-derived AGE-induced neurotoxicity, which is associated with an increase in intracellular reactive oxygen species, as well as against decreases in intracellular catalase (CAT) and superoxide dismutase (SOD) activities. EGCG treatment also decreased malondialdehyde and carbonyl levels, and AGEs formation. Treatment with 10 μM EGCG upregulated SOD and CAT levels, whereas glutathione peroxidase activity was reduced. Furthermore, 5 μM EGCG was found to down-regulate the mRNA level of the AGE receptor (RAGE) in neuronal cells up to 2.5 fold, as determined by real time PCR. The results demonstrated that EGCG may exhibit protective effects against AGEs-induced injury in neuronal cells through its antioxidative properties, as well as by interfering with AGEs-RAGE interaction mediated pathways, suggesting a beneficial role for this tea catechin against neurodegenerative diseases.

Original languageEnglish
Pages (from-to)1369-1373
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume30
Issue number8
DOIs
Publication statusPublished - 2007 Aug 1

Fingerprint

Wounds and Injuries
Tea
Neurodegenerative Diseases
Catalase
Superoxide Dismutase
Glyceraldehyde
Catechin
Polyphenols
Glutathione Peroxidase
Malondialdehyde
epigallocatechin gallate
Real-Time Polymerase Chain Reaction
Reactive Oxygen Species
Down-Regulation
Neurons
Messenger RNA

Keywords

  • (-)-epigallocatechin gallate
  • Advanced glycation endproduct
  • Alzheimer's disease
  • Apoptosis
  • Free radical

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{d50b7fe13ad1465aa761fd5a17520f2d,
title = "Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells",
abstract = "Advanced glycation endproducts (AGEs) are believed to be secondary factors in the selective neuronal injury associated with several neurodegenerative disorders. In this study, we investigated the protective effects of (-)-epigallocatechin gallate (EGCG), a major monomer of green tea polyphenols, against AGEs-induced damage in neuron cells. The results showed that EGCG treatment protected against glyceraldehyde-derived AGE-induced neurotoxicity, which is associated with an increase in intracellular reactive oxygen species, as well as against decreases in intracellular catalase (CAT) and superoxide dismutase (SOD) activities. EGCG treatment also decreased malondialdehyde and carbonyl levels, and AGEs formation. Treatment with 10 μM EGCG upregulated SOD and CAT levels, whereas glutathione peroxidase activity was reduced. Furthermore, 5 μM EGCG was found to down-regulate the mRNA level of the AGE receptor (RAGE) in neuronal cells up to 2.5 fold, as determined by real time PCR. The results demonstrated that EGCG may exhibit protective effects against AGEs-induced injury in neuronal cells through its antioxidative properties, as well as by interfering with AGEs-RAGE interaction mediated pathways, suggesting a beneficial role for this tea catechin against neurodegenerative diseases.",
keywords = "(-)-epigallocatechin gallate, Advanced glycation endproduct, Alzheimer's disease, Apoptosis, Free radical",
author = "Lee, {Sun J.} and Lee, {Kwang Won}",
year = "2007",
month = "8",
day = "1",
doi = "10.1248/bpb.30.1369",
language = "English",
volume = "30",
pages = "1369--1373",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells

AU - Lee, Sun J.

AU - Lee, Kwang Won

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Advanced glycation endproducts (AGEs) are believed to be secondary factors in the selective neuronal injury associated with several neurodegenerative disorders. In this study, we investigated the protective effects of (-)-epigallocatechin gallate (EGCG), a major monomer of green tea polyphenols, against AGEs-induced damage in neuron cells. The results showed that EGCG treatment protected against glyceraldehyde-derived AGE-induced neurotoxicity, which is associated with an increase in intracellular reactive oxygen species, as well as against decreases in intracellular catalase (CAT) and superoxide dismutase (SOD) activities. EGCG treatment also decreased malondialdehyde and carbonyl levels, and AGEs formation. Treatment with 10 μM EGCG upregulated SOD and CAT levels, whereas glutathione peroxidase activity was reduced. Furthermore, 5 μM EGCG was found to down-regulate the mRNA level of the AGE receptor (RAGE) in neuronal cells up to 2.5 fold, as determined by real time PCR. The results demonstrated that EGCG may exhibit protective effects against AGEs-induced injury in neuronal cells through its antioxidative properties, as well as by interfering with AGEs-RAGE interaction mediated pathways, suggesting a beneficial role for this tea catechin against neurodegenerative diseases.

AB - Advanced glycation endproducts (AGEs) are believed to be secondary factors in the selective neuronal injury associated with several neurodegenerative disorders. In this study, we investigated the protective effects of (-)-epigallocatechin gallate (EGCG), a major monomer of green tea polyphenols, against AGEs-induced damage in neuron cells. The results showed that EGCG treatment protected against glyceraldehyde-derived AGE-induced neurotoxicity, which is associated with an increase in intracellular reactive oxygen species, as well as against decreases in intracellular catalase (CAT) and superoxide dismutase (SOD) activities. EGCG treatment also decreased malondialdehyde and carbonyl levels, and AGEs formation. Treatment with 10 μM EGCG upregulated SOD and CAT levels, whereas glutathione peroxidase activity was reduced. Furthermore, 5 μM EGCG was found to down-regulate the mRNA level of the AGE receptor (RAGE) in neuronal cells up to 2.5 fold, as determined by real time PCR. The results demonstrated that EGCG may exhibit protective effects against AGEs-induced injury in neuronal cells through its antioxidative properties, as well as by interfering with AGEs-RAGE interaction mediated pathways, suggesting a beneficial role for this tea catechin against neurodegenerative diseases.

KW - (-)-epigallocatechin gallate

KW - Advanced glycation endproduct

KW - Alzheimer's disease

KW - Apoptosis

KW - Free radical

UR - http://www.scopus.com/inward/record.url?scp=34548027316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548027316&partnerID=8YFLogxK

U2 - 10.1248/bpb.30.1369

DO - 10.1248/bpb.30.1369

M3 - Article

C2 - 17666787

AN - SCOPUS:34548027316

VL - 30

SP - 1369

EP - 1373

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 8

ER -